PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM
Abstract
Authors
K. Moeremans L. Gerlier S. Drieskens L. Annemans H. Brié M. Deruyck P. Faes S. Vancayzeele